ADDF Awards $340,485 Grant to Axxam’s Alzheimer’s Drug Discovery

ADDF Awards $340,485 Grant to Axxam’s Alzheimer’s Drug Discovery

ADDF ACCESSThe Alzheimer's Drug Discovery Foundation (ADDF) has awarded Italian biotechnology company Axxam SpA a $340,485 grant to support the development of novel medication for the treatment of Alzheimer's disease. The company is exploring drugs based on small molecules with the ability to target inflammation directly. It is the third time that the foundation has decided to support Axxam, after having awarded research grants in both 2011 and 2013.

The company will invest the $340,485 grant in its drug discovery project, designed to identify compounds able to selectively block P2X7, the purinergic receptor associated with brain inflammation. Previous research made possible by the two other ADDF grants had already allowed the discovery of a new class of promising P2X7-selective antagonists, which are currently being studied, and are believed to be suitable for in vivo evaluation in pharmacological models soon.

"Compounds that potently and selectively block P2X7 may treat brain inflammation and can potentially be useful in the treatment of Alzheimer's disease and other neurodegenerative diseases," explained the Founding Executive Director and Chief Science Officer at ADDF, Howard Fillit, MD.  "P2X7 is an u

Subscribe or to access all post and page content.